

Protalix BioTherapeutics, Inc.  
Form 8-K  
December 02, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 25, 2008**  
**Protalix BioTherapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

Florida	000-27836	65-0643773
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2 Snunit Street  
Science Park  
POB 455  
Carmiel, Israel 20100**  
(Address of principal executive offices) (Zip Code)

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

**SIGNATURES**

**EX-99.1: PRESS RELEASE**

**EX-99.2: PRESS RELEASE**

---

**Table of Contents**

**Item 7.01. Regulation FD Disclosure**

On November 25, 2008, Protalix BioTherapeutics, Inc. (the Company) issued a press release announcing that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at 1:00 PM ET. The conference is being held at the New York Palace Hotel in New York City. A copy of the press release is furnished as Exhibit 99.1.

An audio webcast of the corporate presentation will be available on the Company's website at [www.protalix.com](http://www.protalix.com) under the events calendar section.

The information in Item 7.01 of this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

**Item 8.01. Other Events**

On December 2, 2008, the Company issued a press release announcing that it has completed enrollment in the Company's pivotal phase III clinical trial of prGCD for the treatment of Gaucher disease, a rare and serious lysosomal storage disorder in humans. A copy of the press release is attached hereto as Exhibit 99.2.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated November 25, 2008.

99.2 Press release dated December 2, 2008.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: December 2, 2008

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer

3